Crescendo Biologics Limited, a Cambridge, UK-based company developing innovative new medicines based on its antibody fragment technology, received an equity investment from Astellas Venture Management (AVM).
The financial details were not disclosed.
The company intends to use the funds for the discovery and development of new Humabody™ antibody fragment therapeutics in oncology.
Led by Mike Romanos , CEO, Crescendo Biologics focuses on the discovery and development of Humabody™ human VH antibody fragment therapeutics, using its transgenic platform. It is enabling the major VH product formats (multivalent, halflife-extended and topical) for its own pipeline, focused in inflammation and oncology, and to partner with other organizations for human VH fragment therapeutics.